Investment Announcement: Kazia Therapeutics Secures $2 Million in a Privately Held Funding Round Conducted Above Market Values
Kazia Therapeutics, an oncology-focused drug development company, has announced the successful completion of a private placement (PIPE) of equity securities. The transaction, expected to close on August 4, 2025, subject to customary conditions, will raise approximately $2 million.
The securities being sold in the PIPE are priced at a 5% premium to the closing price of Kazia's American Depositary Shares (ADSs) on July 31, 2025. The Company plans to offer and sell approximately $2.0 million of ordinary shares and prefunded warrants in the PIPE.
The net proceeds from this offering, estimated to be around $2 million, will be primarily used to support the continued clinical development of Kazia’s lead programs. These include:
- Paxalisib: a brain-penetrant dual PI3K/mTOR inhibitor currently in clinical trials for brain cancer and advanced triple-negative breast cancer.
- EVT801: a selective VEGFR3 inhibitor that is in Phase 1 trials for advanced solid tumors.
Additionally, part of the funds will be allocated for general corporate purposes.
Investors should note that the securities sold in this PIPE are not registered under the Securities Act of 1933 and may not be offered or sold in the United States without an effective registration statement or an applicable exemption. The risks and uncertainties associated with this investment are described more fully in Kazia's Annual Report and subsequent filings with the SEC.
Investors are advised not to place undue reliance on these forward-looking statements, which apply only as of the date of this announcement. The actual results may differ materially from those anticipated in the forward-looking statements. Kazia Therapeutics Limited undertakes no obligation to publicly update any forward-looking statement, except as required under applicable law.
For further inquiries, please contact Alex Star at [email protected] or +1-201-786-8795. The Company also intends to file a shelf registration statement with the U.S. Securities and Exchange Commission within 60 days of the closing to register the resale of ADSs representing the ordinary shares and those underlying the pre-funded warrants.
[1] Kazia Therapeutics Limited. (2025, August 1). Kazia Therapeutics Secures $2 Million through Private Placement of Equity Securities. Business Wire. [2] Kazia Therapeutics Limited. (2025, August 1). Kazia Therapeutics Announces $2 Million Private Placement. GlobeNewswire. [3] Kazia Therapeutics Limited. (2025, August 1). Kazia Therapeutics Announces $2 Million Private Placement. Yahoo Finance. [4] Kazia Therapeutics Limited. (2025, August 1). Kazia Therapeutics Secures $2 Million through Private Placement of Equity Securities. MarketWatch.
- Despite primarily focusing on oncology-focused drug development, Kazia Therapeutics has turned to finance by securing a $2 million investment through a private placement (PIPE) of equity securities.
- The funds raised from this private placement will aid Kazia Therapeutics in advancing its lead programs, such as Paxalisib and EVT801, in clinical trials for brain cancer and advanced triple-negative breast cancer, as well as for general corporate purposes.
